Intuitive Surgical Financial Model
Medical Devices Company Financials Example (Free Excel Download)
Intuitive Surgical (ISRG) is the pioneer and global market leader in robotic-assisted, minimally invasive surgery, primarily through its da Vinci and Ion surgical systems.
professionals from Deloitte
Used by professionals from
About this model
This model projects Intuitive Surgical’s future cash flows and earnings to determine its intrinsic equity valuation, helping an analyst decide whether the stock is a buy, hold, or sell based on the adoption curve of the new da Vinci 5 system and global procedure growth.
Intuitive Surgical (ISRG) is the pioneer and global market leader in robotic-assisted, minimally invasive surgery, primarily through its da Vinci and Ion surgical systems. The company designs, manufactures, and markets these systems, along with the proprietary instruments, accessories, and services required to operate them.
- Business segments: Instruments and Accessories (~60% of revenue), Systems (~24% of revenue), and Services (~16% of revenue).
- Key geographies: United States (~69% of revenue) and Outside the U.S. / OUS (~31% of revenue).
- Business model type: "Razor and razor-blade" model; the company places capital equipment (the razor) and generates highly recurring, high-margin revenue from instruments, accessories, and service contracts (the blades). Recurring revenue accounts for over 80% of total revenue.
- Competitive position: Dominant market leader in soft-tissue robotic surgery with a massive installed base (over 11,100 da Vinci systems globally as of late 2025) and a deep competitive moat driven by surgeon training, hospital capital lock-in, and extensive clinical data.
- Recent major events: The launch and rapid rollout of the next-generation da Vinci 5 system in 2024/2025, significant expansion of the Ion endoluminal system, and macroeconomic headwinds including potential tariff impacts on gross margins.
The downloadable Intuitive Surgical financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsIntuitive Surgical financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $5.71B | $6.22B | $7.12B | $8.35B | $10.06B |
| Gross profit | $3.96B | $4.20B | $4.73B | $5.63B | $6.64B |
| Operating income | $1.82B | $1.58B | $1.77B | $2.35B | $2.95B |
| Net income | $1.70B | $1.32B | $1.80B | $2.32B | $2.86B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Intuitive Surgical
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Instruments and Accessories
- Segment name: Instruments and Accessories
- Revenue driver formula: Total Procedures (da Vinci + Ion) × Average Revenue per Procedure
- Historical growth rate: 17% to 23% YoY
- Key growth levers and headwinds: Driven by procedure volume growth (especially in general surgery like hernia repair and cholecystectomy, and international cancer procedures). Headwinds include hospital staffing shortages, GLP-1 drug impacts on bariatric surgery volumes, and regional volume weakness (e.g., China).
- Pricing dynamics: Contractual pricing with volume-based discounts for large hospital networks. Extended use instruments (which last for more procedures) lower the revenue per procedure slightly but improve hospital economics.
- Revenue recognition notes: Recognised at the point in time when control transfers to the customer (typically upon shipment or delivery).
- Seasonality: Q4 is typically the strongest quarter due to patients exhausting annual health insurance deductibles and scheduling elective surgeries before year-end. Q1 is usually the weakest.
Systems
- Segment name: Systems
- Revenue driver formula: (System Placements × Average Selling Price) + Operating Lease Revenue
- Historical growth rate: 15% to 36% YoY (highly variable based on product cycles)
- Key growth levers and headwinds: Driven by the da Vinci 5 upgrade cycle, greenfield hospital placements, and Ion system adoption. Headwinds include hospital capital budget constraints and trade-in dynamics (where older systems are returned for a discount on new ones).
- Pricing dynamics: A new da Vinci system costs approximately $1.5M to $2.5M. Pricing is heavily influenced by the mix of direct sales versus operating leases, and the mix of da Vinci 5 versus older generation systems.
- Revenue recognition notes: Direct sales are recognised upfront upon delivery/acceptance. Lease revenue is recognised ratably over the lease term. The shift towards leasing defers upfront revenue but builds a larger recurring base.
- Seasonality: Q4 is typically the strongest for capital placements as hospitals exhaust annual capital budgets.
Services
- Segment name: Services
- Revenue driver formula: Installed Base of Systems × Average Annual Service Contract Fee
- Historical growth rate: 10% to 15% YoY
- Key growth levers and headwinds: Directly tied to the cumulative installed base of systems. High renewal rates provide extreme stability.
- Pricing dynamics: Contracts typically range from $100,000 to $200,000 per year per system, covering maintenance, software updates, and technical support.
- Revenue recognition notes: Recognised ratably over the contract period (deferred revenue is created upon billing and amortised over 12 months).
- Seasonality: Minimal seasonality due to ratable revenue recognition.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Direct materials, manufacturing labour, overhead, freight, tariffs, and depreciation of leased systems.
- Gross margin range: 66.0% to 69.5% (Non-GAAP) over the last 5 years.
- Key input costs and commodity exposures: Electronic components, specialised metals, and global freight. Tariffs (especially on components from China) are a material headwind.
- How COGS scales with revenue: High operating leverage on software and services, but physical instruments have linear material costs. Depreciation of leased systems creates a fixed cost layer in COGS.
Operating Expenses
- R&D: ~11% to 13% of revenue. Covers next-generation robotics (da Vinci 5), digital tools, AI/machine learning integration, and clinical trials. Expensed as incurred.
- SG&A: ~24% to 26% of revenue. Heavily driven by the direct sales force, clinical training teams, and marketing. Headcount-driven.
- Depreciation & Amortisation: Embedded within COGS (for leased systems) and operating expenses (for facilities/equipment).
- Stock-Based Compensation: Significant expense, typically running at 7% to 9% of revenue, reflecting the competitive tech/medtech labour market in California.
- Restructuring / one-time charges: Rare, but the company occasionally makes large charitable contributions to the Intuitive Foundation (e.g., $70M in Q4 2025).
Margin Profile
- Gross margin: 66% - 69%
- Operating margin: 25% - 30%
- Net margin: 22% - 26%
- Margin trend: Slight near-term compression due to the da Vinci 5 launch (higher manufacturing costs initially), increased depreciation from leased systems, and tariff impacts, but long-term stable.
Balance Sheet Structure
- Total assets: ~$19.3 billion
- Key asset categories: Cash, cash equivalents, and short-term investments (~$9.0 billion); Inventory (~$1.5 billion); Property, Plant and Equipment (~$4.8 billion).
- Goodwill & intangibles: Very low (<5% of assets) as Intuitive is primarily an organic grower, not a serial acquirer.
- Working capital profile:
- DSO: 45 - 55 days
- DIO: 100 - 130 days (high inventory needed to support complex manufacturing and global supply chain)
- DPO: 30 - 45 days
- Net working capital as % of revenue: Positive, typically 15% - 20%.
- PP&E: Consists of manufacturing facilities (California, Georgia, Mexico, Europe), training centres, and systems leased to customers.
- Right-of-use assets / operating leases: Material due to global facility footprint, but manageable relative to total assets.
Capital Expenditure & Investment
- Capex as % of revenue: 8% - 12% (elevated recently due to manufacturing footprint expansion).
- Maintenance capex vs. growth capex: ~30% maintenance / 70% growth (building new manufacturing hubs and expanding global direct operations).
- Major capex programmes underway: Expansion of manufacturing facilities in California, Georgia, and international markets to support da Vinci 5 and Ion.
- Capitalised software / development costs: Minimal; most R&D is expensed.
- M&A pattern: Organic grower. Occasional small bolt-on acquisitions for specific technologies (e.g., digital tools, imaging) or buying out regional distributors (e.g., direct operations in Italy, Spain).
Debt & Capital Structure
- Total debt: $0. Intuitive Surgical operates with a pristine, debt-free balance sheet.
- Debt/EBITDA ratio: 0.0x.
- Credit rating: Unrated (no debt).
- Key debt instruments: None.
- Share repurchase programme: Highly active. The company uses its massive free cash flow to buy back stock (e.g., repurchased $1.92 billion in Q3 2025).
- Dividend policy: No dividend. 100% of return of capital is via share repurchases.
Cash Flow Characteristics
- Operating cash flow conversion: Consistently >1.0x of Net Income due to high stock-based compensation add-backs and depreciation.
- Free cash flow margin: 20% - 25% of revenue.
- Major non-cash items: Stock-based compensation ($800M+ annually) and depreciation of leased systems.
- Working capital cash flow impact: Inventory builds consume cash during new product launches (da Vinci 5), but deferred revenue from service contracts provides a steady cash inflow.
- Capex intensity: Moderate to high currently (8-12%) due to facility expansions, but historically lower.
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are often lower than GAAP taxes due to excess tax benefits from stock-based compensation.
Sheet Structure
- Assumptions: Hardcoded inputs for procedure growth, system placements, ASPs, margins, tax rate, and working capital days.
- Procedures & Installed Base: Schedule calculating da Vinci procedures, Ion procedures, system placements (sales vs. leases), and the roll-forward of the installed base.
- Revenue Schedule: Revenue broken out strictly by Instruments and Accessories, Systems, and Services.
- Income Statement: Revenue down to Net Income, matching the 10-K format (COGS, Gross Profit, SG&A, R&D, Operating Income, Interest/Other Income, Tax, Net Income).
- Balance Sheet: Assets (Cash, AR, Inventory, Prepaids, PP&E, ROU Assets) and Liabilities/Equity (AP, Accrued Comp, Deferred Revenue, Lease Liabilities, Retained Earnings).
- Cash Flow Statement: OCF (Net Income + D&A + SBC + Deferred Taxes + WC changes), ICF (Capex, Investments), FCF (Share Repurchases).
- Debt & Interest Schedule: Blank/zeroed out for debt, but calculates interest income on the $9B+ cash balance.
- PP&E & Depreciation Schedule: Tracks capex, depreciation of corporate assets, and depreciation of leased systems.
- Working Capital Schedule: Calculates AR, Inv, AP, and Deferred Revenue based on days assumptions.
- DCF Valuation: Unlevered free cash flow calculation, WACC, terminal value, and implied share price.
Key Financial Relationships
- `Ending Installed Base = Beginning Installed Base + System Placements - Retirements/Trade-ins`
- `Total Procedures = Beginning Installed Base × Average Procedures per System per Year`
- `Instruments & Accessories Revenue = Total Procedures × Average I&A Revenue per Procedure`
- `Systems Revenue = (Direct System Sales × ASP) + Operating Lease Revenue`
- `Services Revenue = Average Installed Base for the Period × Annual Service Contract Fee`
- `Total Revenue = Instruments & Accessories Revenue + Systems Revenue + Services Revenue`
- `COGS = Total Revenue × (1 - Gross Margin %)`
- `R&D Expense = Total Revenue × R&D % of Revenue`
- `SG&A Expense = Total Revenue × SG&A % of Revenue`
- `Operating Income = Total Revenue - COGS - R&D Expense - SG&A Expense`
- `Interest Income = Average Cash & Investments Balance × Yield on Cash`
- `Net Income = (Operating Income + Interest Income) × (1 - Effective Tax Rate)`
- `Free Cash Flow = Net Income + D&A + Stock-Based Comp - Change in NWC - Capex`
- `Diluted Shares Outstanding = Beginning Shares - (Share Repurchases / Average Share Price) + Shares Issued via SBC`
Cross-Sheet Dependencies
- The Procedures & Installed Base sheet is the engine of the model; it feeds directly into the Revenue Schedule.
- The Revenue Schedule feeds the top line of the Income Statement and drives the Working Capital Schedule (AR, Deferred Revenue).
- The Income Statement generates Net Income, which is the starting point for the Cash Flow Statement.
- The Cash Flow Statement calculates the ending cash balance, which feeds the Balance Sheet.
- The Balance Sheet cash balance feeds the Debt & Interest Schedule to calculate interest income, which flows back to the Income Statement (minor circularity, easily resolved with an average balance toggle or iteration).
- The PP&E & Depreciation Schedule feeds D&A into the Income Statement (COGS for leased systems, Opex for facilities) and the Cash Flow Statement.
Sign Convention
- Revenues and Assets: Positive.
- Expenses and Liabilities: Positive in their specific schedules, but subtracted in aggregation formulas (e.g., `Gross Profit = Revenue - COGS`).
- Cash Flow Statement: Inflows are positive (e.g., Net Income, D&A, increase in AP). Outflows are negative (e.g., Capex, Share Repurchases, increase in AR).
- Contra-accounts: Accumulated Depreciation is negative on the Balance Sheet.
Things Most Likely to Go Wrong
- Lease Accounting Complexity: Intuitive places a significant number of systems under operating leases. Failing to split system placements into "sales" vs "leases" will drastically overstate near-term revenue and understate long-term recurring revenue.
- Stock-Based Compensation: ISRG has massive SBC (~$800M+ annually). If this is not added back in the Cash Flow Statement, Operating Cash Flow will be severely understated.
- Interest Income: With ~$9 billion in cash, interest income is a material contributor to pre-tax income. Forgetting to model yield on cash will understate EPS.
- Tariff Impacts: Gross margins are highly sensitive to tariffs on Chinese components. The model must allow for gross margin compression (e.g., 50-100 bps) based on tariff scenarios.
- Trade-in Dynamics: As hospitals upgrade to da Vinci 5, they trade in older systems. This lowers the blended ASP of systems sold. The model must account for trade-in discounts.
- Tax Rate Volatility: The GAAP tax rate fluctuates wildly due to excess tax benefits from stock-based compensation. The model should use a normalised pro-forma tax rate (22-23%) for forecasting.
- Foundation Contributions: ISRG occasionally drops $40M-$70M into its foundation in Q4. This should be modelled as a recurring but lumpy SG&A expense.
- Procedure Mix: Ion procedures grow much faster (40%+) than da Vinci procedures (15%+), but generate less revenue per procedure. Blending them without weighting will skew I&A revenue forecasts.
Validation Checks
- "Recurring Revenue (I&A + Services + Operating Leases) should be >80% of Total Revenue; flag if it drops below 80%."
- "Gross margin should be in the 66.0% - 69.0% range; flag if outside this band."
- "Operating margin should remain between 25% and 30%."
- "Total Debt must equal $0. Interest expense must equal $0."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Cash flow conversion (OCF / Net Income) should be >1.1x due to heavy SBC."
- "Capex as % of revenue should run between 8% and 12%."
- "Total procedure growth should not exceed 20% YoY without a manual override flag."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Total Procedure Growth | 14.5 | % | Midpoint of management's 2026 guidance (13-16%) |
| Da Vinci System Placements | 1,600 | Units | Assumes moderate growth over 2024's 1,526 placements driven by da Vinci 5 |
| System Lease Mix | 50.0 | % | Continued hospital preference for capital-light acquisition models |
| Average System ASP (Direct Sale) | 1.60 | $M | Blended rate accounting for da Vinci 5 premium offset by trade-ins |
| I&A Revenue per Procedure | 1,850 | $ | Historical average, slightly declining as extended-use instruments scale |
| Annual Service Fee per System | 150,000 | $ | Historical average for comprehensive service contracts |
| Gross Margin (Non-GAAP) | 67.5 | % | Midpoint of management's 2026 guidance (67-68%) |
| R&D as % of Revenue | 11.5 | % | Continued heavy investment in digital, AI, and next-gen platforms |
| SG&A as % of Revenue | 25.0 | % | Historical average, scaling slightly with revenue growth |
| Effective Tax Rate (Pro Forma) | 22.5 | % | Midpoint of management's 2025/2026 guidance (22-23%) |
| Yield on Cash & Investments | 4.5 | % | Assumes current short-term treasury/corporate paper yields |
| Share Repurchases | 1,500 | $M | Assumes continued aggressive return of capital |
| Diluted Share Count | 356.6 | Millions | Actual Q3 2025 diluted share count |
| WACC | 8.5 | % | Low beta, zero debt, high market risk premium |
| Terminal Growth Rate | 3.5 | % | Premium to GDP due to long-term secular tailwinds in robotic surgery |
Data Sources & Benchmarks
- Filings: SEC EDGAR (Form 10-K, 10-Q, 8-K) and Intuitive Surgical Investor Relations page (isrg.gcs-web.com).
- Key peers for benchmarking: Medtronic (MDT - Hugo system), Johnson & Johnson (JNJ - Ottava system), Stryker (SYK - Mako system).
- Industry data sources: American College of Surgeons (ACS) for procedure volumes, hospital capital expenditure surveys (e.g., from Piper Sandler or JP Morgan).
- Consensus estimates source: FactSet or Bloomberg for forward procedure growth and EPS estimates.
- Proprietary data: Hospital purchasing databases (e.g., Definitive Healthcare) to track da Vinci 5 adoption and trade-in rates.
Sources
- Intuitive Surgical Q4 2024 Earnings Release (January 2025)
- Intuitive Surgical Q4 2025 Earnings Release (January 2026)
- Intuitive Surgical Q3 2025 Form 10-Q (October 2025)
- Intuitive Surgical Q2 2025 Earnings Release (July 2025)
- Intuitive Surgical Q1 2025 Earnings Release (April 2025)
- Seeking Alpha: Intuitive Surgical Analysis (March 2026)
Do more with the Intuitive Surgical model
Frequently asked
What does Intuitive Surgical (ISRG) do?+
Intuitive Surgical (ISRG) is the global market leader in robotic-assisted, minimally invasive surgery, primarily through its da Vinci and Ion surgical systems. The company designs, manufactures, and markets these systems, along with the proprietary instruments, accessories, and services required for their operation.
How does Intuitive Surgical generate revenue?+
Intuitive Surgical operates on a "razor and razor-blade" business model, where it places capital equipment (the systems) and generates highly recurring, high-margin revenue from instruments, accessories, and service contracts. Recurring revenue accounts for over 80% of its total revenue.
What are Intuitive Surgical's capital expenditure plans?+
Intuitive Surgical's capital expenditure (Capex) is typically 8% to 12% of revenue, currently elevated due to significant manufacturing footprint expansion. Approximately 70% of this capex is growth-oriented, focused on building new manufacturing hubs and expanding global direct operations.
What is the purpose of the Intuitive Surgical financial model?+
The financial model projects Intuitive Surgical's future cash flows and earnings to determine its intrinsic equity valuation. This helps analysts decide whether the stock is a buy, hold, or sell, based on factors like the adoption curve of the new da Vinci 5 system and global procedure growth.
Can I download a financial model for Intuitive Surgical (ISRG)?+
Yes, a downloadable Excel financial model for Intuitive Surgical (ISRG) is available. This model provides a forecast horizon from FY2026 through FY2030 for the company's financial performance.
What is Intuitive Surgical's competitive advantage in the market?+
Intuitive Surgical holds a dominant market leader position in soft-tissue robotic surgery, supported by a massive installed base of over 11,100 da Vinci systems globally. Its deep competitive moat is driven by extensive surgeon training, hospital capital lock-in, and a wealth of clinical data.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Medical Devices Company Financial Models
Browse another company in the same sector.
Abbott Laboratories
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products.
Align Technology
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
Baxter International
Baxter International Inc.
Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products.
Boston Scientific
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties.
Cooper Companies
The Cooper Companies, Inc.
Dexcom
Dexcom is a medical device company focused on the design, development, and commercialisation of continuous glucose monitoring systems that provide real-time glucose readings for people with diabetes, replacing traditional fingerstick testing.
Edwards Lifesciences
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease.
Explore more Healthcare financial model templates.
